Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Migvax Ltd. is engaged in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. This level of activity points to a targeted prosecution strategy for its biological or pharmaceutical innovations. The company's interaction with the USPTO is currently limited to 1 distinct examiner, which simplifies the communication channel for its legal team and allows for a focused prosecution effort.
The presence of 1 distinct art unit indicates that the company's applications are being reviewed within a specific technical niche in the Biotechnology & Pharmaceuticals sector. This concentration in 1 distinct art unit allows for a deep focus on the specific patentability standards applicable to that area. For the practitioner, managing the 1 pending office action involves navigating the specific technical requirements of this single unit and its 1 distinct examiner.
JADHAO, SAMADHAN JAISING is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending office action. Since this 1 action is the only one pending for Migvax Ltd., the examiner's individual review process is the most significant factor in the portfolio's progress. Addressing the 1 busiest examiner pending office action from JADHAO, SAMADHAN JAISING is the critical step for advancing the company's intellectual property in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278682 | ORAL COMPOSITIONS AND USE OF SAME IN VACCINATION | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278682 | ORAL COMPOSITIONS AND USE OF SAME IN VACCINATION | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278682 | ORAL COMPOSITIONS AND USE OF SAME IN VACCINATION | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112 | Non-Final OA | — | Pending | Aug 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMigvax Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samadhan Jaising Jadhao has the most, with 1 of Migvax Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
